Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes

被引：1
|
作者：
Nowak, Albina [1 ]
Mechtler, Thomas P. [2 ]
Desnick, Robert J. [3 ]
Kasper, David C. [4 ]
机构：
[1] Univ Zurich Hosp, Zurich, Switzerland
[2] Univ Hosp Zurich, Vienna, Austria
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] ARCHIMED Life Sci, Vienna, Austria
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
Biomarker; Fabry disease; Heterozygotes; LysoGb3; α-galactosidase deficiency;
D O I：
10.1016/j.ymgme.2016.11.262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
253
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [41] The relationship between multiple plasma biomarker levels and renal disease activity in Fabry disease
    Seyda Gul Ozcan
    Necmi Eren
    Mevlut Tamer Dincer
    Zeynep Atli
    Murat Bolayirli
    Metin Ergul
    Hakan Ozer
    Kultigin Turkmen
    Sinan Trabulus
    Nurhan Seyahi
    BMC Nephrology, 26 (1)
  • [42] A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
    Shin, Seok-Ho
    Park, Min-Ho
    Byeon, Jin-Ju
    Lee, Byeong Ill
    Park, Yuri
    Ko, Ah-ra
    Seong, Mi-ran
    Lee, Soyeon
    Kim, Mi Ra
    Seo, Jinwook
    Jung, Myung Eun
    Jin, Dong-Kyu
    Shin, Young G.
    PHARMACEUTICS, 2018, 10 (02):
  • [43] Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease
    Shu, Liming
    Vivekanandan-Giri, Anuradha
    Pennathur, Subramaniam
    Smid, Bouwien E.
    Aerts, Johannes M. F. G.
    Hollak, Carla E. M.
    Shayman, James A.
    KIDNEY INTERNATIONAL, 2014, 86 (01) : 58 - 66
  • [44] Novel Gb3 Isoforms Detected in Urine of Fabry Disease Patients: A Metabolomic Study
    Auray-Blais, C.
    Boutin, M.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (19) : 3241 - 3252
  • [45] Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features
    Ranieri, Michela
    Bedini, Gloria
    Parati, Eugenio Agostino
    Bersano, Anna
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2016, 18 (07)
  • [46] Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
    Politei, Juan M.
    Bouhassira, Didier
    Germain, Dominique P.
    Goizet, Cyril
    Guerrero-Sola, Antonio
    Hilz, Max J.
    Hutton, Elspeth J.
    Karaa, Amel
    Liguori, Rocco
    Ueceyler, Nurcan
    Zeltzer, Lonnie K.
    Burlina, Alessandro
    CNS NEUROSCIENCE & THERAPEUTICS, 2016, 22 (07) : 568 - 576
  • [47] Deficient α-galactosidase A activity in plasma but no Fabry disease -: a pitfall in diagnosis
    Hoffmann, B
    Koch, HG
    Schweitzer-Krantz, S
    Wendell, U
    Mayatepek, E
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (11) : 1276 - 1277
  • [48] Plasma adiponectin is a potential biomarker for organ involvement in male Fabry disease patients
    Hovakimyan, Marina
    Talabattula, Venkata Ajay Narendra
    Cozma, Claudia
    Beetz, Christian
    Rolfs, Arndt
    Elstein, Deborah
    BLOOD CELLS MOLECULES AND DISEASES, 2020, 80
  • [49] Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features
    Michela Ranieri
    Gloria Bedini
    Eugenio Agostino Parati
    Anna Bersano
    Current Treatment Options in Neurology, 2016, 18
  • [50] Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease
    Ueceyler, N.
    Boettger, J.
    Henkel, L.
    Langjahr, M.
    Mayer, C.
    Nordbeck, P.
    Wanner, C.
    Sommer, C.
    JOURNAL OF INTERNAL MEDICINE, 2018, 284 (04) : 427 - 438
12345